SEC filing record
Primary Source · SEC.gov

Indaptus Therapeutics, Inc.

2025 vintageRule 506(c)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-06-20Last filing 2025-06-20

Raised

$2M

Investors

20

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Indaptus Therapeutics, Inc. is a Delaware corporation that first filed a Form D on August 5, 2021 and most recently amended it on June 20, 2025 in the Pharmaceuticals industry group. The offering claims Rule 506(c). Indaptus Therapeutics, Inc. reported $2,314,800 sold from 20 investors of a $5,000,000 total offering as of the Form D filed June 20, 2025. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Paulson Investment Company, LLC (CRD 000005670), associated with None as the recipient of sales compensation soliciting in CA, CO, FL, GA, HI, ID, IL, KS, MA, MD, MI, MN, NC, NJ, NV, NY, OK, OR, PA, SC, TX, UT, VA, WA, WI. Sales commissions are reported as $600,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 3 Columbus Circle, 15th Floor, New York, NY 10019.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001857044
Entity NameIndaptus Therapeutics, Inc.
ExemptionRule 506(c)
What the exemption meansRule 506(c) of Regulation D: the issuer may advertise the offering publicly, but every purchaser must be a verified accredited investor.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address3 Columbus Circle, 15th Floor, New York, NY 10019
Phone(646) 427-2727
Former NamesIntec Parent Inc. (until August 3, 2021)
Industry / Fund TypePharmaceuticals
Securities Type—
First Sale DateJune 12, 2025
Filing DateJune 20, 2025
Accession Number0001641172-25-015841
Total Offering Amount$5,000,000
Total Amount Sold$2,314,800
Amount Remaining$2,685,200
Amount Sold NoteCombined figure across related vehicles: Offering of convertible notes in the aggregate principal amount of up to $5 million, convertible into shares of common stock, together with warrants to purchase shares of common stock. Approximately $2.3 million raised as of initial closing date.
Total Investors20
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$600,000 (to Paulson Investment Company, LLC)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)NY
Amendment Count6 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

4

latest Jun 20, 2025

Critical / warning

0 / 0

0 watch · 4 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed, lapsed

Latest event New filer · Jun 20, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 4 filing events with values and deltas, latest 2025-06-20, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Jeffrey A. Meckler

Executive Officer, Director · New York, NY

Michael J Newman

Executive Officer, Director · New York, NY

Nir J Sassi

Executive Officer · New York, NY

Walt A. Linscott

Executive Officer · New York, NY

Roger J. Waltzman

Executive Officer · New York, NY

Roger J. Pomerantz

Director · New York, NY

Hila J. Karah

Director · New York, NY

Anthony J. Maddaluna

Director · New York, NY

William B. Hayes

Director · New York, NY

Mark J. Gilbert

Director · New York, NY

Robert E. Martell

Director · New York, NY

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Paulson Investment Company, LLCCRD 000005670 on BrokerCheck

Associated broker-dealer: None · Portland, OR · Soliciting in CA, CO, FL, GA, HI, ID, IL, KS, MA, MD, MI, MN, NC, NJ, NV, NY, OK, OR, PA, SC, TX, UT, VA, WA, WI and outside the United States

Questions About Indaptus Therapeutics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Indaptus Therapeutics, Inc.?

Indaptus Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on June 20, 2025 in the Pharmaceuticals industry group. The filing claims Rule 506(c).

Is Indaptus Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Indaptus Therapeutics, Inc. filed a Form D with the SEC on June 20, 2025 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $2,314,800 sold to 20 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Indaptus Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Indaptus Therapeutics, Inc. claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Indaptus Therapeutics, Inc. raised?

Indaptus Therapeutics, Inc. reported $2,314,800 sold from 20 investors of a $5,000,000 total offering as of the Form D filed June 20, 2025. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone.

Who can invest in Indaptus Therapeutics, Inc.?

The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Indaptus Therapeutics, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Indaptus Therapeutics, Inc. and how are they paid?

The Form D names Paulson Investment Company, LLC (CRD 000005670), associated with None as the recipient of sales compensation soliciting in CA, CO, FL, GA, HI, ID, IL, KS, MA, MD, MI, MN, NC, NJ, NV, NY, OK, OR, PA, SC, TX, UT, VA, WA, WI. Sales commissions are reported as $600,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Indaptus Therapeutics, Inc.?

The Form D lists 11 related persons: Jeffrey A. Meckler, executive officer, director; Michael J Newman, executive officer, director; Nir J Sassi, executive officer; Walt A. Linscott, executive officer; Roger J. Waltzman, executive officer; Roger J. Pomerantz, director; Hila J. Karah, director; Anthony J. Maddaluna, director, and 3 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Indaptus Therapeutics, Inc. located?

The issuer's address on its SEC filings is 3 Columbus Circle, 15th Floor, New York, NY 10019. Its phone number of record is (646) 427-2727. It is organized under the laws of Delaware.

How long is the Indaptus Therapeutics, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is Indaptus Therapeutics, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.